Blog

Aparna Parikh: So much to be excited about at ASCO this year

Aparna Raj Parikh/LinkedIn

May 31, 2025, 10:00

Aparna Parikh: So much to be excited about at ASCO this year

Aparna Parikh, Associate Professor of Medicine at Harvard Medical School and a Gastrointestinal Oncologist at Massachusetts General Hospital, shared a post by Ariel Carmeli, Co-founder of Reversing Early Recurrence, on LinkedIn, adding:

“So much to be excited about at ASCO this year (including big year for GI!) but this initiative is at the very top.

In November, we launched RER, a nonprofit initiative dedicated to advancing the evidence base for ctDNA in ways we felt weren’t happening fast or rigorously enough.

We believe that with the right therapies, combined with a deep, evidence-based and evolving understanding of ctDNA, we can accelerate the shift of more treatments into earlier — and potentially curative — settings.”

Quoting Arial Carmeli’s post:

“Excited to attend ASCO25 and for the chance to share more about our work at RER (Reversing Early Recurrence) to help bring novel cancer treatments sooner when patients could benefit most.

This will be our first ASCO as a RER team – a lean, committed group assembling a state-of-the-art cancer care ecosystem to intercept cancer recurrence at its earliest stage, based on ctDNA, and give patients a possible opportunity for a cure.

In an article published in Nature Reviews Cancer we outlined how this system could speed drug development for solid tumors — enabling faster, cheaper, and smaller clinical trials by engaging the more than 100,000 patients who have been treated for an early-stage cancer but are at risk that the cancer will recur.

My co-authors include industry luminaries: Aparna Parikh, MD and Arielle Medford, MD, Mass General Cancer Center; Levi Garraway, MD/PhD and Nikhil Wagle, MD, Genentech; Eric S. Lander, PhD and Alex Ritchie, Science for America.

Please reach out if you are attending ASCO25 this weekend and interested to explore the transformative possibilities of novel treatments in earlier settings! Would love to connect across the ecosystem, with oncologists, drug developers, diagnostics, and tech innovators.”

You can find more posts regarding ASCO 2025 on OncoDaily.